Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04257487
Other study ID # FAAI2.10.2018
Secondary ID 2019-000570-33
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 21, 2020
Est. completion date December 2, 2023

Study information

Verified date July 2022
Source Arianna Anticoagulazione Foundation
Contact Cristina Legnani, BSc, PhD
Phone 0039 051 2812339
Email c.legnani@fondazionearianna.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.


Description:

This prospective cohort study aims to assess the efficacy and safety of the extended treatment with Sulodexide (Vessel®) in the secondary prevention of DVT / PE recurrence in elderly outpatients (≥ 75 years old at the time of inclusion) ), with at least one of the known bleeding risk factor, who had a first episode of lower extremity proximal DVT and / or PE, idiopathic or associated with weak or removed risk factors, and who have received standard treatment with any oral anticoagulant drug lasting at least 3 months. The study seeks to verify the safety of the Sulodexide therapy, demonstrating non-inferiority compared to placebo, with an incidence of major bleeding around 1% (upper confidence limit not > 3%).


Recruitment information / eligibility

Status Recruiting
Enrollment 1455
Est. completion date December 2, 2023
Est. primary completion date September 2, 2023
Accepts healthy volunteers No
Gender All
Age group 75 Years and older
Eligibility Inclusion Criteria: 1. Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors. 2. Patients aged =75 years at the time of enrolment 3. Patients with at least one of the known risk factors of bleeding (APPENDIX 1): 1. Hypertension 2. Renal failure 3. Thrombocytopenia 4. Diabetes 5. Antiplatelet therapy (ASA maximum 140 mg/die) 6. Frequent falls (>2 /years) 7. Nonsteroidal anti-inflammatory drug 8. Liver failure 9. Previous Stroke 10. Anemia 11. Poor anticoagulant control 12. Alcohol abuse 4. Patients of both sexes. 5. Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days. 6. Patients with no other AT indications. 7. Patients capable and able to provide informed consent Exclusion Criteria: 1. Patients aged <75 years at the time of the recruitment visit. 2. "Provoked" index event, which occurred: - Within 3 months of surgery or major trauma, - Bed Rest > 4 days, - Cast / immobility within 3 months. 3. Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy. 4. Index event represented by isolated distal DVT or superficial venous thrombosis. 5. Thrombotic event in sites other than the deep proximal veins of the lower limbs. 6. Anticoagulant therapy for less than 3 months at the time of enrolment. 7. Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment 8. Recurrent episodes of DVT ± PE

Study Design


Intervention

Drug:
Sulodexide
2 soft capsules of Vessel® 250 LSU BID for 12 months
Sulodexide and placebo
1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
Placebo
Sugar pill manufactured to mimic sulodexide 250 LSU

Locations

Country Name City State
Italy Corrado Lodigiani Rozzano

Sponsors (1)

Lead Sponsor Collaborator
Arianna Anticoagulazione Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy). The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients From date of enrollment until the date of first documented event assessed up to 12 months
Primary Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety) Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients From date of enrollment until the date of first documented event assessed up to 12 months
Secondary Number of and rate of thromboembolic events Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients From date of enrollment until the date of first documented event assessed up to 12 months
Secondary Presence of severe post-thrombotic syndrome according to Villalta Score Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score > of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome 12 months
Secondary Number and rate of non major bleeding complications In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation From date of enrollment until the date of first documented event assessed up to 12 months
Secondary Number and rate of dead patients (overall mortality) VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients From date of enrollment until the date of first documented event assessed up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05347550 - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients N/A
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Completed NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
Completed NCT01976988 - Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery Phase 3